文献速递肝病

基线HDV-RNA水平可在肝硬化前分层慢性丁型肝炎临床风险

Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study.
PubMed 文献 · Aliment Pharmacol Ther · 2026-04-20

这项欧洲多中心回顾-前瞻性队列研究纳入260例未治疗且HDV-RNA可检测的慢性丁型肝炎成人,评估基线HDV-RNA与肝脏相关事件的关系。中位随访4.1年,28%患者发生至少一次肝脏相关事件,肝硬化者发生率显著更高。非肝硬化患者中基线HDV-RNA越高肝脏相关事件比例越高,最低病毒载量类别无事件;肝硬化患者中基线HDV-RNA与事件无关。

要点

  • 未治疗慢性丁型肝炎患者中,基线定量HDV-RNA可用于肝硬化发生前的早期风险分层。
  • 非肝硬化患者基线HDV-RNA升高与肝脏相关事件比例增加一致相关,最低类别无事件。
  • 一旦肝硬化建立,临床结局 largely 独立于病毒复制,基线HDV-RNA不再分层风险。

核心结论

  • 基线定量HDV-RNA可在未治疗慢性丁型肝炎患者发展为肝硬化前进行早期风险分层。
  • 肝硬化建立后,临床结局 largely 独立于病毒复制,需优先早期抗病毒干预和密切监测。

研究设计与样本

  • 多中心回顾-前瞻性队列研究,纳入260例未治疗且HDV-RNA可检测的慢性丁型肝炎成人。
  • 患者来自西班牙推导队列(n=98)和两个意大利验证队列(n=100和n=62)。
  • 基线血清qHDV-RNA从6 IU/mL起按1-log增量分类。

主要发现

  • 中位随访4.1年,74例(28%)发生至少一次肝脏相关事件,肝硬化者发生率显著高于非肝硬化者(p<0.001)。
  • 非肝硬化患者中,基线HDV-RNA升高在推导和验证队列中均与肝脏相关事件比例增高一致相关,最低HDV-RNA类别无事件。
  • 已建立肝硬化的患者中,基线HDV-RNA水平与肝脏相关事件发生无关,各病毒载量类别累积发生率相当。

关键数值与推荐

  • 基线血清qHDV-RNA从6 IU/mL起按1-log增量分类。
  • 中位随访4.1年,74/260例(28%)发生至少一次肝脏相关事件。
  • 肝硬化患者肝脏相关事件发生率显著高于非肝硬化患者(p<0.001)。

临床怎么用

  • 对未治疗慢性丁型肝炎患者在肝硬化发生前检测基线定量HDV-RNA,用于早期风险分层。
  • 对非肝硬化且HDV-RNA较高者应优先考虑及时抗病毒干预和密切监测。
  • 已建立肝硬化者不能仅依据基线HDV-RNA分层风险,仍需密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic hepatitis D (CHD) is associated with rapid progression to liver cirrhosis. However, the prognostic relevance of quantitative serum HDV-RNA remains incompletely defined. We aimed to evaluate whether baseline HDV-RNA levels are associated with the risk of liver-related events in untreated patients with CHD and to validate these findings in two independent European cohorts. METHODS: We conducted a multicentre retrospective-prospective cohort study including 260 untreated adults with CHD and detectable HDV-RNA. Patients were derived from a Spanish derivation cohort (n = 98) and two Italian validation cohorts (n = 100 and n = 62). Baseline serum qHDV-RNA was categorized in 1-log increments starting from 6 IU/mL. RESULTS: During a median follow-up of 4.1 years, 74 patients (28%) experienced at least one liver-related event, with a significantly higher incidence in patients with cirrhosis than in those without cirrhosis (p < 0.001). Among noncirrhotic patients, increasing baseline HDV-RNA levels were consistently associated with a higher proportion of liver-related events across derivation and validation cohorts, whereas no events occurred at the lowest HDV-RNA category. In contrast, among patients with established cirrhosis, baseline HDV-RNA levels were not associated with the occurrence of liver-related events, and cumulative incidence was comparable across viral load categories. CONCLUSIONS: Baseline quantitative HDV-RNA allows early risk stratification in untreated patients with chronic hepatitis D before the development of liver cirrhosis. Once cirrhosis is established, clinical outcomes are largely independent of viral replication, emphasising the need to prioritise timely antiviral intervention and close surveillance at earlier disease stages.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Palom A, Degasperi E, Coco B, et al. Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study. Aliment Pharmacol Ther. 2026. PMID: 42010908. doi:10.1111/apt.70695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。